RT Journal Article
SR Electronic
T1 Plasma CD105, TGFβ-1, TGFβ-3 and the Ligand/Receptor Complexes in Children with Acute Lymphoblastic Leukaemia
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 543
OP 547
VO 26
IS 1B
A1 AL-MOWALLAD, ABDULFATTAH
A1 CARR, TREVOR
A1 AL-QOUZI, ABDULLAH
A1 LI, CHENGGANG
A1 BYERS, RICHARD
A1 KUMAR, SHANT
YR 2006
UL http://ar.iiarjournals.org/content/26/1B/543.abstract
AB The role of angiogenesis in solid tumours is well recognised, but its importance in haematological malignancies is less well understood. In leukaemia, mainly the determination of microvascular density utilising immunohistochemistry in the bone marrow trephines and the measurement of soluble angiogenic factors have led to the recognition that angiogenesis may be important in leukaemia as well. In this study, the soluble form of the endothelial cell activation/proliferation (i.e., angiogenesis) marker CD105 and its ligands TGFβ-1 and -3, as well as the ligand/receptor complexes in plasma from children with acute lymphoblastic leukaemia (ALL) were quantified. The plasma level of CD105 was significantly higher in patients with common ALL compared to controls, while the TGFβ-3 level was lower in patients. Neither the CD105 or TGFβ-3 levels were of prognostic value, nor did they correlate with any of the known prognostic indicators, such as white blood cell counts. There were no significant differences between the plasma levels of any of the other parameters, such as TGFβ-1 or the ligand receptor complexes, in children with leukaemia compared to controls. Our results support the role of angiogenesis in leukaemia and suggest that anti-angiogenesis may be a therapeutic target in leukaemia. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved